JDQ-443

Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.

The global KRAS inhibitor market is projected to grow from $108.1 million in 2023 to $186.4 million by 2033, exhibiting a CAGR of 5.6%.

The KRAS inhibitors market is projected to grow significantly, driven by increasing cancer incidence and advancements in targeted therapies.

Several companies are actively developing novel therapies for HER2-mutant non-small cell lung cancer (NSCLC), indicating a robust pipeline.

IAG933 directly disrupts the YAP/TAZ-TEAD protein-protein interaction, leading to YAP eviction from chromatin and reduced Hippo-mediated transcription.